Cargando…
Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better?
(1) Background: The current study aimed to compare two of the most frequently prescribed preservative-free (PF) antiglaucoma drops, (Latanoprost PF vs. Bimatoprost PF) in promoting OSD in patients with POAG. (2) Methods: In this prospective study, 44 eyes from 44 participants were included. In the c...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648670/ https://www.ncbi.nlm.nih.gov/pubmed/37959198 http://dx.doi.org/10.3390/jcm12216732 |
_version_ | 1785135392661438464 |
---|---|
author | Dimtsas, Georgios S. Tsiogka, Anastasia Moschos, Marilita M. |
author_facet | Dimtsas, Georgios S. Tsiogka, Anastasia Moschos, Marilita M. |
author_sort | Dimtsas, Georgios S. |
collection | PubMed |
description | (1) Background: The current study aimed to compare two of the most frequently prescribed preservative-free (PF) antiglaucoma drops, (Latanoprost PF vs. Bimatoprost PF) in promoting OSD in patients with POAG. (2) Methods: In this prospective study, 44 eyes from 44 participants were included. In the control group we enrolled 24 eyes, 11 eyes treated only with Latanoprost PF were enrolled in the Latanoprost PF group, and 9 eyes treated only with Bimatoprost PF in the Bimatoprost PF group. In all eyes, we evaluated the ocular levels of MMP-9 using the InflammaDry kit. We also performed Schirmer’s test and the TBUT test. (3) Results: We found elevated ocular levels of MMP-9 (>40 ng/mL) in the Bimatoprost PF group (88.89% of the participants) compared to the control (8.33%) and the Latanoprost PF group (27.27%), and the difference was statistically significant (p < 0.001). The Schirmer’s test values were statistically significantly lower in the Bimatoprost PF group compared to the other two groups. Additionally, the TBUT values were lower in the Bimatoprost PF group compared to the control group, and the difference was statistically significant. (4) Conclusions: Latanoprost PF eye drops treat the ocular surface better and they do not induce overexpression of MMP-9, a molecule that is related to OSD. |
format | Online Article Text |
id | pubmed-10648670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106486702023-10-25 Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better? Dimtsas, Georgios S. Tsiogka, Anastasia Moschos, Marilita M. J Clin Med Article (1) Background: The current study aimed to compare two of the most frequently prescribed preservative-free (PF) antiglaucoma drops, (Latanoprost PF vs. Bimatoprost PF) in promoting OSD in patients with POAG. (2) Methods: In this prospective study, 44 eyes from 44 participants were included. In the control group we enrolled 24 eyes, 11 eyes treated only with Latanoprost PF were enrolled in the Latanoprost PF group, and 9 eyes treated only with Bimatoprost PF in the Bimatoprost PF group. In all eyes, we evaluated the ocular levels of MMP-9 using the InflammaDry kit. We also performed Schirmer’s test and the TBUT test. (3) Results: We found elevated ocular levels of MMP-9 (>40 ng/mL) in the Bimatoprost PF group (88.89% of the participants) compared to the control (8.33%) and the Latanoprost PF group (27.27%), and the difference was statistically significant (p < 0.001). The Schirmer’s test values were statistically significantly lower in the Bimatoprost PF group compared to the other two groups. Additionally, the TBUT values were lower in the Bimatoprost PF group compared to the control group, and the difference was statistically significant. (4) Conclusions: Latanoprost PF eye drops treat the ocular surface better and they do not induce overexpression of MMP-9, a molecule that is related to OSD. MDPI 2023-10-25 /pmc/articles/PMC10648670/ /pubmed/37959198 http://dx.doi.org/10.3390/jcm12216732 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dimtsas, Georgios S. Tsiogka, Anastasia Moschos, Marilita M. Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better? |
title | Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better? |
title_full | Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better? |
title_fullStr | Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better? |
title_full_unstemmed | Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better? |
title_short | Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better? |
title_sort | latanoprost pf vs. bimatoprost pf: which treats the ocular surface better? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648670/ https://www.ncbi.nlm.nih.gov/pubmed/37959198 http://dx.doi.org/10.3390/jcm12216732 |
work_keys_str_mv | AT dimtsasgeorgioss latanoprostpfvsbimatoprostpfwhichtreatstheocularsurfacebetter AT tsiogkaanastasia latanoprostpfvsbimatoprostpfwhichtreatstheocularsurfacebetter AT moschosmarilitam latanoprostpfvsbimatoprostpfwhichtreatstheocularsurfacebetter |